ApolloMed And Helynx To Present Results Of Predictive Analytics Study At Artificial Intelligence In Medicine Conference

GLENDALE, Calif., Dec. 7, 2016 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (OTC: AMEH), an integrated population health management company, and Helynx, Inc., a technology company that has developed a next-generation machine learning and data discovery platform, today announced that they will present the results of a study based on ApolloMed ACO patients at AI Med, a Multidisciplinary Symposium on Artificial Intelligence in Medicine.

The conference, which takes place from December 12-15 in Laguna Niguel, California, covers the use of cognitive computing, deep learning and other leading-edge analytics and "Big Data" techniques in medicine and healthcare. Helynx and ApolloMed's study, "Predicting Admissions and Emergency Department Visits from Time-Lagged ACO-Specific Data" was performed by feeding three years of de-identified claims data on nearly 30,000 ApolloMed ACO Medicare patients into Helynx's analytics engine.   Helynx implemented a large scale multivariate computational model based on all available data.  Even constrained by 60- to 90-day old claims data, the multivariate predictor outperformed traditional methods in early identification of at-risk patients.

The study was carried out by Chess Stetson, Ph.D, Boris Revechkis, Ph.D and Kris Chaisanguanthum, Ph.D from Helynx and Diane Pham, M.D. from ApolloMed.

"Our collaboration with Helynx continues to produce interesting insights," stated Warren Hosseinion, MD, Chief Executive Officer of Apollo Medical Holdings. "Our goal is to use this actionable information to more accurately predict patient emergency department visits and admissions in order to reduce avoidable hospitalizations, improve patient outcomes and to reduce healthcare expenditures."

"Machine learning, combined with expert clinical knowledge, can provide completely new insights into improving patient care and reducing the cost of care," stated Chess Stetson, Ph.D., Chief Executive Officer of Helynx, Inc. "We are looking forward to presenting how we have generated some of these insights, using a new kind of tool that reveals patterns that you may not even have known you were looking for."

About Apollo Medical Holdings, Inc.

Headquartered in Glendale, California, ApolloMed is an integrated population health management company committed to providing exceptional multi-disciplinary care in the communities it serves.  ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups:  ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), ApolloMed Care Clinics, Apollo Care Connect and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit www.apollomed.net

Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. ("the Company").  In particular, when used in the preceding discussion, the words "predicts," "believes," "expects," "intends," "seeks," "estimates," "plans," "anticipates," and similar conditional expressions or future or conditional verbs such as "will," "may," "might," "should," "would" and "could" are intended to identify forward-looking statements.  In addition, our representatives may from time to time make oral forward-looking statements.  Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company's management.  Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected.  Unknown or unpredictable factors also could have material adverse effects on the Company's future results.  The forward-looking statements included herein are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements.  Accordingly, you should not place undue reliance on these forward-looking statements.  Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended March 31, 2016 and in any of the Company's other subsequent Securities and Exchange Commission filings.

FOR ADDITIONAL INFORMATION
Gary Augusta
818-839-5200 or via email at gaugusta@apollomed.net

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apollomed-and-helynx-to-present-results-of-predictive-analytics-study-at-artificial-intelligence-in-medicine-conference-300374369.html

SOURCE Apollo Medical Holdings, Inc.